Pharming Group to report fourth quarter and full year 2023 financial results on March 14

Rhea-AI Summary

Pharming Group N.V. announces the release of its preliminary financial results for Q4 and full year 2023 on March 14, 2024, with a presentation scheduled for analysts and investors. The company will host a conference call and live webcast for participants to engage with management and ask questions.

Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.
Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 14, 2024.
To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.

Conference call registration:

Please note, the Company will only take questions from dial-in attendees.

https://register.vevent.com/register/BIc993931aa2d54aa89d594b2cad5ed972

To watch the live webcast, please register in advance using the link below.

Webcast registration:

https://edge.media-server.com/mmc/p/5wi4ajdm

About Pharming Group N.V.

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:

Pharming Group, Leiden, The Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com

FTI Consulting, London, UK
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

 

FAQ

When will Pharming Group N.V. report its preliminary financial results for Q4 and full year 2023?

Pharming Group N.V. will report its preliminary (unaudited) financial results for Q4 and full year 2023 on March 14, 2024.

What time is the presentation for analysts and investors scheduled on March 14, 2024?

The presentation for analysts and investors is scheduled at 13:30 CET/08:30 am EDT on March 14, 2024.

How can participants join the conference call for Pharming Group N.V.?

Participants can join the conference call by registering in advance using the provided link and dial-in information with a unique PIN.

Is there a live webcast available for Pharming Group N.V.'s presentation?

Yes, participants can watch the live webcast by registering in advance using the provided link.